32 results on '"Erin M. Coffee"'
Search Results
2. Supplementary Figures from mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
- Author
-
Jeffrey A. Engelman, Cyril H. Benes, Kenneth E. Hung, Sridhar Ramaswamy, Miguel N. Rivera, Ryan B. Corcoran, Rakesh K. Jain, David P. Kodack, Jatin Roper, Randy J. Milano, Jessica L. Boisvert, Ah Ting Tam, Youngchul Song, Elena J. Edelman, Alan T. Yeo, Aaron N. Hata, Hiromichi Ebi, Anahita Dastur, Carlotta Costa, Erin M. Coffee, and Anthony C. Faber
- Abstract
PDF file 764K, Supp. Figures 1-10 include data describing in vitro and in vivo experiments in support of Faber at al
- Published
- 2023
3. Supplementary Figures 1-9, Table 1, Methods from EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- Author
-
Jeffrey A. Engelman, Mari Mino-Kenudson, Jeffrey Settleman, Jennifer A. Wargo, Adriano Piris, Keith T. Flaherty, Kenneth E. Hung, Dora Dias-Santagata, Patricia Della Pelle, Ronald D. Brown, Alexandria P. Cogdill, Michiya Nishino, Erin M. Coffee, Alexa B. Turke, Hiromichi Ebi, and Ryan B. Corcoran
- Abstract
PDF file - 417K
- Published
- 2023
4. Supplementary Figure S3 from Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
- Author
-
Kenneth E. Hung, Umar Mahmood, Julie L. C. Kan, Matthew G. Vander Heiden, Ramnik J. Xavier, Roderick T. Bronson, Todd VanArsdale, Scott L. Weinrich, John Lamb, Tao Xie, Zhi Xie, Xiadong Ji, Gautam Goel, Sophia Y. Lunt, Pedram Heidari, Lydia Lee, Jatin Roper, Erin M. Coffee, Jing Yuan, Larissa Georgeon Richard, Mark J. Sinnamon, Peter J. Belmont, and Eric S. Martin
- Abstract
PDF file - 29 KB, Comparison of metabolic readouts in AP and AKP cell lines
- Published
- 2023
5. Data from Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
- Author
-
Kenneth E. Hung, Eric S. Martin, Jeffrey A. Engelman, Ramnik J. Xavier, Sabine Tejpar, Roderick T. Bronson, Barbara J. Weinstein, Veerle de Vriendt, Loredana Vecchione, Wei Vivian Wang, Lily Keung, Gautam Goel, Mark J. Sinnamon, Jatin Roper, Anthony C. Faber, and Erin M. Coffee
- Abstract
Purpose:BRAFV600E mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAFV600E CRC.Experimental Design: We examined phosphoinositide 3-kinase (PI3K)/mTOR signaling in BRAFV600E CRC cell lines after BRAF inhibition and cell viability and apoptosis after combined BRAF and PI3K/mTOR inhibition. We assessed the efficacy of in vivo combination treatment using a novel genetically engineered mouse model (GEMM) for BRAFV600E CRC.Results: Western blot analysis revealed sustained PI3K/mTOR signaling upon BRAF inhibition. Our BRAFV600E GEMM presented with sessile serrated adenomas/polyps, as seen in humans. Combination treatment in vivo resulted in induction of apoptosis and tumor regression.Conclusions: We have established a novel GEMM to interrogate BRAFV600E CRC biology and identify more efficacious treatment strategies. Combination BRAF and PI3K/mTOR inhibitor treatment should be explored in clinical trials. Clin Cancer Res; 19(10); 2688–98. ©2013 AACR.
- Published
- 2023
6. Supplementary Table S2 from Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
- Author
-
Kenneth E. Hung, Umar Mahmood, Julie L. C. Kan, Matthew G. Vander Heiden, Ramnik J. Xavier, Roderick T. Bronson, Todd VanArsdale, Scott L. Weinrich, John Lamb, Tao Xie, Zhi Xie, Xiadong Ji, Gautam Goel, Sophia Y. Lunt, Pedram Heidari, Lydia Lee, Jatin Roper, Erin M. Coffee, Jing Yuan, Larissa Georgeon Richard, Mark J. Sinnamon, Peter J. Belmont, and Eric S. Martin
- Abstract
XLS file - 25 KB, Top 5 Ingenuity Pathway Analysis biological functions represented in GEMM AP vs AKP signature
- Published
- 2023
7. Supplementary Figure 1 from Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
- Author
-
Kenneth E. Hung, Eric S. Martin, Jeffrey A. Engelman, Ramnik J. Xavier, Sabine Tejpar, Roderick T. Bronson, Barbara J. Weinstein, Veerle de Vriendt, Loredana Vecchione, Wei Vivian Wang, Lily Keung, Gautam Goel, Mark J. Sinnamon, Jatin Roper, Anthony C. Faber, and Erin M. Coffee
- Abstract
Supplementary Figure 1 PDF file 118K, Development a GEMM for BRAFV600E CRC
- Published
- 2023
8. Supplementary Text from Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
- Author
-
Kenneth E. Hung, Umar Mahmood, Julie L. C. Kan, Matthew G. Vander Heiden, Ramnik J. Xavier, Roderick T. Bronson, Todd VanArsdale, Scott L. Weinrich, John Lamb, Tao Xie, Zhi Xie, Xiadong Ji, Gautam Goel, Sophia Y. Lunt, Pedram Heidari, Lydia Lee, Jatin Roper, Erin M. Coffee, Jing Yuan, Larissa Georgeon Richard, Mark J. Sinnamon, Peter J. Belmont, and Eric S. Martin
- Abstract
PDF file - 151 KB, Supplemental text including supplemental methods, supplemental figure and table legends, and supplemental references.
- Published
- 2023
9. Supplementary Figure 2 from Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
- Author
-
Kenneth E. Hung, Eric S. Martin, Jeffrey A. Engelman, Ramnik J. Xavier, Sabine Tejpar, Roderick T. Bronson, Barbara J. Weinstein, Veerle de Vriendt, Loredana Vecchione, Wei Vivian Wang, Lily Keung, Gautam Goel, Mark J. Sinnamon, Jatin Roper, Anthony C. Faber, and Erin M. Coffee
- Abstract
Supplementary Figure 2 PDF file 152K, APC tumors do not recapitulate the sessile serrated CRC pathway
- Published
- 2023
10. Supplementary Figure Legends from Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
- Author
-
Kenneth E. Hung, Eric S. Martin, Jeffrey A. Engelman, Ramnik J. Xavier, Sabine Tejpar, Roderick T. Bronson, Barbara J. Weinstein, Veerle de Vriendt, Loredana Vecchione, Wei Vivian Wang, Lily Keung, Gautam Goel, Mark J. Sinnamon, Jatin Roper, Anthony C. Faber, and Erin M. Coffee
- Abstract
Supplementary Figure Legends PDF file 89K, Supplementary Figure Legends for Supplementary Figure 1 and Supplementary Figure 2
- Published
- 2023
11. Data from Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
- Author
-
Kenneth E. Hung, Umar Mahmood, Julie L. C. Kan, Matthew G. Vander Heiden, Ramnik J. Xavier, Roderick T. Bronson, Todd VanArsdale, Scott L. Weinrich, John Lamb, Tao Xie, Zhi Xie, Xiadong Ji, Gautam Goel, Sophia Y. Lunt, Pedram Heidari, Lydia Lee, Jatin Roper, Erin M. Coffee, Jing Yuan, Larissa Georgeon Richard, Mark J. Sinnamon, Peter J. Belmont, and Eric S. Martin
- Abstract
Purpose: Effective therapies for KRAS-mutant colorectal cancer (CRC) are a critical unmet clinical need. Previously, we described genetically engineered mouse models (GEMM) for sporadic Kras-mutant and non-mutant CRC suitable for preclinical evaluation of experimental therapeutics. To accelerate drug discovery and validation, we sought to derive low-passage cell lines from GEMM Kras-mutant and wild-type tumors for in vitro screening and transplantation into the native colonic environment of immunocompetent mice for in vivo validation.Experimental Design: Cell lines were derived from Kras-mutant and non-mutant GEMM tumors under defined media conditions. Growth kinetics, phosphoproteomes, transcriptomes, drug sensitivity, and metabolism were examined. Cell lines were implanted in mice and monitored for in vivo tumor analysis.Results:Kras-mutant cell lines displayed increased proliferation, mitogen-activated protein kinase signaling, and phosphoinositide-3 kinase signaling. Microarray analysis identified significant overlap with human CRC-related gene signatures, including KRAS-mutant and metastatic CRC. Further analyses revealed enrichment for numerous disease-relevant biologic pathways, including glucose metabolism. Functional assessment in vitro and in vivo validated this finding and highlighted the dependence of Kras-mutant CRC on oncogenic signaling and on aerobic glycolysis.Conclusions: We have successfully characterized a novel GEMM-derived orthotopic transplant model of human KRAS-mutant CRC. This approach combines in vitro screening capability using low-passage cell lines that recapitulate human CRC and potential for rapid in vivo validation using cell line-derived tumors that develop in the colonic microenvironment of immunocompetent animals. Taken together, this platform is a clear advancement in preclinical CRC models for comprehensive drug discovery and validation efforts. Clin Cancer Res; 19(11); 2929–40. ©2013 AACR.
- Published
- 2023
12. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
- Author
-
Jatin Roper, Michael P Richardson, Wei Vivian Wang, Larissa Georgeon Richard, Wei Chen, Erin M Coffee, Mark J Sinnamon, Lydia Lee, Peng-Chieh Chen, Roderick T Bronson, Eric S Martin, and Kenneth E Hung
- Subjects
Medicine ,Science - Abstract
To examine the in vitro and in vivo efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA wild-type colorectal cancer (CRC).PIK3CA mutant and wild-type human CRC cell lines were treated in vitro with NVP-BEZ235, and the resulting effects on proliferation, apoptosis, and signaling were assessed. Colonic tumors from a genetically engineered mouse (GEM) model for sporadic wild-type PIK3CA CRC were treated in vivo with NVP-BEZ235. The resulting effects on macroscopic tumor growth/regression, proliferation, apoptosis, angiogenesis, and signaling were examined.In vitro treatment of CRC cell lines with NVP-BEZ235 resulted in transient PI3K blockade, sustained decreases in mTORC1/mTORC2 signaling, and a corresponding decrease in cell viability (median IC(50) = 9.0-14.3 nM). Similar effects were seen in paired isogenic CRC cell lines that differed only in the presence or absence of an activating PIK3CA mutant allele. In vivo treatment of colonic tumor-bearing mice with NVP-BEZ235 resulted in transient PI3K inhibition and sustained blockade of mTORC1/mTORC2 signaling. Longitudinal tumor surveillance by optical colonoscopy demonstrated a 97% increase in tumor size in control mice (p = 0.01) vs. a 43% decrease (p = 0.008) in treated mice. Ex vivo analysis of the NVP-BEZ235-treated tumors demonstrated a 56% decrease in proliferation (p = 0.003), no effects on apoptosis, and a 75% reduction in angiogenesis (p = 0.013).These studies provide the preclinical rationale for studies examining the efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA wild-type CRC.
- Published
- 2011
- Full Text
- View/download PDF
13. mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
- Author
-
Kenneth E. Hung, Sridhar Ramaswamy, Erin M. Coffee, Cyril H. Benes, Carlotta Costa, Aaron N. Hata, Youngchul Song, Miguel Rivera, Hiromichi Ebi, Rakesh K. Jain, Anthony C. Faber, Ah Ting Tam, Randy J. Milano, Ryan B. Corcoran, Anahita Dastur, Jessica L. Boisvert, Alan T. Yeo, David P. Kodack, Elena J. Edelman, Jatin Roper, and Jeffrey A. Engelman
- Subjects
Proto-Oncogene Proteins B-raf ,Colorectal cancer ,Morpholines ,medicine.medical_treatment ,bcl-X Protein ,Mice, Nude ,Antineoplastic Agents ,Mechanistic Target of Rapamycin Complex 2 ,mTORC1 ,Mechanistic Target of Rapamycin Complex 1 ,Biology ,medicine.disease_cause ,Article ,Targeted therapy ,Proto-Oncogene Proteins p21(ras) ,Mice ,chemistry.chemical_compound ,Cell Line, Tumor ,Proto-Oncogene Proteins ,medicine ,Animals ,Humans ,Protein Kinase Inhibitors ,neoplasms ,PI3K/AKT/mTOR pathway ,Sulfonamides ,Mutation ,Aniline Compounds ,Navitoclax ,TOR Serine-Threonine Kinases ,medicine.disease ,Mice, Mutant Strains ,digestive system diseases ,Proto-Oncogene Proteins c-bcl-2 ,Oncology ,chemistry ,Apoptosis ,Multiprotein Complexes ,ras Proteins ,Cancer research ,Myeloid Cell Leukemia Sequence 1 Protein ,KRAS ,Colorectal Neoplasms - Abstract
Colorectal cancers harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug screen, we have developed a novel therapeutic strategy that targets the apoptotic machinery using the BCL-2 family inhibitor ABT-263 (navitoclax) in combination with a TORC1/2 inhibitor, AZD8055. This combination leads to efficient apoptosis specifically in KRAS- and BRAF-mutant but not wild-type (WT) colorectal cancer cells. This specific susceptibility results from TORC1/2 inhibition leading to suppression of MCL-1 expression in mutant, but not WT, colorectal cancers, leading to abrogation of BIM/MCL-1 complexes. This combination strategy leads to tumor regressions in both KRAS-mutant colorectal cancer xenograft and genetically engineered mouse models of colorectal cancer, but not in the corresponding KRAS-WT colorectal cancer models. These data suggest that the combination of BCL-2/BCL-XL inhibitors with TORC1/2 inhibitors constitutes a promising targeted therapy strategy to treat these recalcitrant cancers. Significance: Effective targeted therapies directed against colorectal cancer with activating mutations in KRAS remain elusive. We have leveraged drug-screen data from a large panel of human colorectal cancers to uncover an effective, rational targeted therapy strategy that has preferential activity in colorectal cancers with KRAS or BRAF mutations. This combination may be developed for clinical testing. Cancer Discov; 4(1); 42–52. ©2013 AACR. See related commentary by Russo et al., p. 19 This article is highlighted in the In This Issue feature, p. 1
- Published
- 2014
14. Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
- Author
-
Eric S. Martin, Gautam Goel, Erin M. Coffee, Loredana Vecchione, Barbara Weinstein, Roderick T. Bronson, Lily Keung, Jatin Roper, Mark J. Sinnamon, Anthony C. Faber, Sabine Tejpar, Kenneth E. Hung, Jeffrey A. Engelman, Ramnik J. Xavier, Wei Vivian Wang, and Veerle De Vriendt
- Subjects
Proto-Oncogene Proteins B-raf ,Cancer Research ,endocrine system diseases ,Cell Survival ,Colorectal cancer ,Blotting, Western ,Apoptosis ,Biology ,Article ,Mice ,Phosphatidylinositol 3-Kinases ,Cell Line, Tumor ,medicine ,Animals ,Humans ,skin and connective tissue diseases ,Protein Kinase Inhibitors ,neoplasms ,PI3K/AKT/mTOR pathway ,Cell Proliferation ,Phosphoinositide-3 Kinase Inhibitors ,Mice, Knockout ,Dose-Response Relationship, Drug ,Cell growth ,TOR Serine-Threonine Kinases ,Melanoma ,Cancer ,Neoplasms, Experimental ,HCT116 Cells ,medicine.disease ,digestive system diseases ,Tumor Burden ,Blot ,enzymes and coenzymes (carbohydrates) ,Indenes ,Oncology ,Mutation ,Cancer research ,Pyrazoles ,Experimental pathology ,Colorectal Neoplasms ,Signal Transduction - Abstract
Purpose: BRAFV600E mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAFV600E CRC. Experimental Design: We examined phosphoinositide 3-kinase (PI3K)/mTOR signaling in BRAFV600E CRC cell lines after BRAF inhibition and cell viability and apoptosis after combined BRAF and PI3K/mTOR inhibition. We assessed the efficacy of in vivo combination treatment using a novel genetically engineered mouse model (GEMM) for BRAFV600E CRC. Results: Western blot analysis revealed sustained PI3K/mTOR signaling upon BRAF inhibition. Our BRAFV600E GEMM presented with sessile serrated adenomas/polyps, as seen in humans. Combination treatment in vivo resulted in induction of apoptosis and tumor regression. Conclusions: We have established a novel GEMM to interrogate BRAFV600E CRC biology and identify more efficacious treatment strategies. Combination BRAF and PI3K/mTOR inhibitor treatment should be explored in clinical trials. Clin Cancer Res; 19(10); 2688–98. ©2013 AACR.
- Published
- 2013
15. Mutations in the promoter region of the aldolase B gene that cause hereditary fructose intolerance
- Author
-
Erin M. Coffee and Dean R. Tolan
- Subjects
Male ,Hereditary fructose intolerance ,DNA Mutational Analysis ,Mutant ,Mutation, Missense ,Fructose-bisphosphate aldolase ,Transfection ,Article ,Exon ,Fructose-Bisphosphate Aldolase ,Genetics ,medicine ,Humans ,Genetic Testing ,Promoter Regions, Genetic ,Enhancer ,Cells, Cultured ,Genetics (clinical) ,biology ,Aldolase B ,Intron ,Infant ,Promoter ,Hispanic or Latino ,medicine.disease ,Fructose Intolerance ,Molecular biology ,Black or African American ,Child, Preschool ,biology.protein ,Female - Abstract
Hereditary fructose intolerance (HFI) is a potentially fatal inherited metabolic disease caused by a deficiency of aldolase B activity in the liver and kidney. Over 40 disease-causing mutations are known in the protein-coding region of ALDOB. Mutations upstream of the protein-coding portion of ALDOB are reported here for the first time. DNA sequence analysis of 61 HFI patients revealed single base mutations in the promoter, intronic enhancer, and the first exon, which is entirely untranslated. One mutation, g.–132G>A, is located within the promoter at an evolutionarily conserved nucleotide within a transcription factor-binding site. A second mutation, IVS1+1G>C, is at the donor splice site of the first exon. In vitro electrophoretic mobility shift assays show a decrease in nuclear extract-protein binding at the g.–132G>A mutant site. The promoter mutation results in decreased transcription using luciferase reporter plasmids. Analysis of cDNA from cells transfected with plasmids harboring the IVS1+1G>C mutation results in aberrant splicing leading to complete retention of the first intron (~ 5 kb). The IVS1+1G>C splicing mutation results in loss of luciferase activity from a reporter plasmid. These novel mutations in ALDOB represent 2% of alleles in American HFI patients, with IVS1+1G>C representing a significantly higher allele frequency (6%) among HFI patients of Hispanic and African-American ethnicity.
- Published
- 2010
16. Gluconeogenesis
- Author
-
Erin M. Coffee and Dean R. Tolan
- Published
- 2014
17. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
- Author
-
Peter J. Belmont, Erin M. Coffee, Lily Keung, Anthony C. Faber, Ömer H. Yilmaz, Roderick T. Bronson, Eric S. Martin, Philip N. Tsichlis, Kenneth E. Hung, Jihye Yun, Larissa Georgeon-Richard, Wei Vivian Wang, Jatin Roper, Mark J. Sinnamon, Koch Institute for Integrative Cancer Research at MIT, and Yilmaz, Omer
- Subjects
MAPK/ERK pathway ,Cancer Research ,Class I Phosphatidylinositol 3-Kinases ,Colorectal cancer ,Mutant ,Apoptosis ,mTORC1 ,medicine.disease_cause ,Article ,Mice ,Phosphatidylinositol 3-Kinases ,medicine ,Animals ,Humans ,Enzyme Inhibitors ,neoplasms ,PI3K/AKT/mTOR pathway ,Phosphoinositide-3 Kinase Inhibitors ,Chemistry ,Wild type ,Cancer ,MAP Kinase Kinase Kinases ,medicine.disease ,Molecular biology ,digestive system diseases ,Mice, Inbred C57BL ,Genes, ras ,Oncology ,Mutation ,Cancer research ,KRAS ,Colorectal Neoplasms - Abstract
PI3K inhibition in combination with other agents has not been studied in the context of PIK3CA wild-type, KRAS mutant cancer. In a screen of phospho-kinases, PI3K inhibition of KRAS mutant colorectal cancer cells activated the MAPK pathway. Combination PI3K/MEK inhibition with NVP-BKM120 and PD-0325901 induced tumor regression in a mouse model of PIK3CA wild-type, KRAS mutant colorectal cancer, which was mediated by inhibition of mTORC1, inhibition of MCL-1, and activation of BIM. These findings implicate mitochondrial-dependent apoptotic mechanisms as determinants for the efficacy of PI3K/MEK inhibition in the treatment of PIK3CA wild-type, KRAS mutant cancer. Keywords: PI3K; MEK; KRAS; Colorectal cancer; Mouse model of cancer
- Published
- 2014
18. Cross-species analysis of genetically engineered mouse models of MAPK driven colorectal cancer identifies hallmarks of human disease
- Author
-
Eva Budinská, Ping Jiang, Peter J. Belmont, Mauro Delorenzi, Paul A. Rejto, Erin M. Coffee, Kenneth E. Hung, Sabine Tejpar, Eric S. Martin, Owen J. Sansom, Mark J. Sinnamon, Sahra Derkits, Tao Xie, and Jatin Roper
- Subjects
Proto-Oncogene Proteins B-raf ,Colorectal cancer ,Neuroscience (miscellaneous) ,lcsh:Medicine ,Medicine (miscellaneous) ,Disease ,Biology ,Genomic signatures ,Bioinformatics ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,BRAF ,law.invention ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Species Specificity ,Immunology and Microbiology (miscellaneous) ,law ,Genotype ,KRAS ,lcsh:Pathology ,medicine ,Animals ,Humans ,Allele ,Alleles ,030304 developmental biology ,0303 health sciences ,Drug discovery ,lcsh:R ,medicine.disease ,MAPK ,3. Good health ,Disease Models, Animal ,Genes, ras ,GEMM ,030220 oncology & carcinogenesis ,Genetically Engineered Mouse ,Cancer research ,Suppressor ,Mitogen-Activated Protein Kinases ,Colorectal Neoplasms ,Research Article ,lcsh:RB1-214 - Abstract
Effective treatment options for advanced colorectal cancer (CRC) are limited, survival rates are poor, and this disease continues to be a leading cause of cancer-related deaths worldwide. Despite being a highly heterogeneous disease, a significant subset of patients with sporadic CRC typically harbor relatively few established 'driver' lesions. Here, we describe a collection of genetically engineered mouse models (GEMM) of sporadic CRC that combine lesions frequently altered in human patients, including well-characterized tumor suppressors and activators of MAPK signaling. Primary tumors from these models were profiled, and individual GEMM tumors segregated into groups based on their genotypes. Unique allelic and genotypic expression signatures were generated from these GEMMs and applied to clinically annotated human CRC patient samples. We provide evidence that a Kras signature derived from these GEMMs is capable of distinguishing KRAS mutant patients, and tracks with poor prognosis in two independent human patient cohorts. Further, the analysis of a panel of human CRC cell lines suggests that high expression of the GEMM Kras signature correlates with sensitivity to targeted pathway inhibitors. Together, these findings implicate GEMMs as powerful preclinical tools with the capacity to recapitulate relevant human disease biology, and support the use of genetic signatures generated in these models to facilitate future drug discovery and validation efforts.
- Published
- 2014
19. Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
- Author
-
Eric S. Martin, Erin M. Coffee, Julie L.C. Kan, Gautam Goel, Kenneth E. Hung, Sophia Y. Lunt, Scott L. Weinrich, Zhi Xie, Matthew G. Vander Heiden, Jing Yuan, Lydia Lee, Xiadong Ji, Pedram Heidari, Larissa Georgeon Richard, John Lamb, Umar Mahmood, Tao Xie, Roderick T. Bronson, Jatin Roper, Mark J. Sinnamon, Peter J. Belmont, Ramnik J. Xavier, Todd VanArsdale, Massachusetts Institute of Technology. Department of Biology, Koch Institute for Integrative Cancer Research at MIT, Lunt, Sophia Yunkyungkwon, and Vander Heiden, Matthew G.
- Subjects
Cancer Research ,Genes, APC ,Genotype ,Carcinogenesis ,Colorectal cancer ,Mice, Transgenic ,Biology ,medicine.disease_cause ,Mice ,Phosphatidylinositol 3-Kinases ,In vivo ,Cell Line, Tumor ,medicine ,Animals ,Cluster Analysis ,Humans ,Lactic Acid ,Wnt Signaling Pathway ,neoplasms ,Microarray analysis techniques ,Gene Expression Profiling ,TOR Serine-Threonine Kinases ,Wnt signaling pathway ,Cancer ,Genes, p53 ,medicine.disease ,Xenograft Model Antitumor Assays ,Molecular biology ,digestive system diseases ,Transplantation ,Disease Models, Animal ,Glucose ,Oncology ,Colonic Neoplasms ,Mutation ,ras Proteins ,Cancer research ,KRAS ,Mitogen-Activated Protein Kinases ,Signal Transduction - Abstract
Purpose: Effective therapies for KRAS-mutant colorectal cancer (CRC) are a critical unmet clinical need. Previously, we described genetically engineered mouse models (GEMM) for sporadic Kras-mutant and non-mutant CRC suitable for preclinical evaluation of experimental therapeutics. To accelerate drug discovery and validation, we sought to derive low-passage cell lines from GEMM Kras-mutant and wild-type tumors for in vitro screening and transplantation into the native colonic environment of immunocompetent mice for in vivo validation. Experimental Design: Cell lines were derived from Kras-mutant and non-mutant GEMM tumors under defined media conditions. Growth kinetics, phosphoproteomes, transcriptomes, drug sensitivity, and metabolism were examined. Cell lines were implanted in mice and monitored for in vivo tumor analysis. Results: Kras-mutant cell lines displayed increased proliferation, mitogen-activated protein kinase signaling, and phosphoinositide-3 kinase signaling. Microarray analysis identified significant overlap with human CRC-related gene signatures, including KRAS-mutant and metastatic CRC. Further analyses revealed enrichment for numerous disease-relevant biologic pathways, including glucose metabolism. Functional assessment in vitro and in vivo validated this finding and highlighted the dependence of Kras-mutant CRC on oncogenic signaling and on aerobic glycolysis. Conclusions: We have successfully characterized a novel GEMM-derived orthotopic transplant model of human KRAS-mutant CRC. This approach combines in vitro screening capability using low-passage cell lines that recapitulate human CRC and potential for rapid in vivo validation using cell line-derived tumors that develop in the colonic microenvironment of immunocompetent animals. Taken together, this platform is a clear advancement in preclinical CRC models for comprehensive drug discovery and validation efforts. Clin Cancer Res; 19(11); 2929–40. ©2013 AACR.
- Published
- 2013
20. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
- Author
-
Jeffrey Settleman, Hiromichi Ebi, Adriano Piris, Jeffrey A. Engelman, Ryan B. Corcoran, Mari Mino-Kenudson, Jennifer A. Wargo, Erin M. Coffee, Ronald D. Brown, Patricia Della Pelle, Dora Dias-Santagata, Alexa B. Turke, Alexandria P. Cogdill, Kenneth E. Hung, Keith T. Flaherty, and Michiya Nishino
- Subjects
MAPK/ERK pathway ,Male ,Proto-Oncogene Proteins B-raf ,Indoles ,endocrine system diseases ,Colorectal cancer ,MAP Kinase Signaling System ,Mutant ,Mice, Nude ,Cell Growth Processes ,Biology ,Article ,Mice ,Encorafenib ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Vemurafenib ,skin and connective tissue diseases ,neoplasms ,Sulfonamides ,Melanoma ,medicine.disease ,Immunohistochemistry ,Xenograft Model Antitumor Assays ,digestive system diseases ,ErbB Receptors ,enzymes and coenzymes (carbohydrates) ,Oncology ,Cancer research ,raf Kinases ,Colorectal Neoplasms ,HT29 Cells ,medicine.drug - Abstract
BRAF mutations occur in 10% to 15% of colorectal cancers and confer adverse outcome in the metastatic setting. Although RAF inhibitors such as vemurafenib (PLX4032) have proven effective in the treatment of BRAF-mutant melanoma, they are surprisingly ineffective in BRAF-mutant colorectal cancers, and the reason for this disparity remains unclear. Compared with BRAF-mutant melanoma cells, BRAF-mutant colorectal cancer cells were less sensitive to vemurafenib, and phospho-extracellular signal-regulated kinase (P-ERK) suppression was not sustained in response to treatment. Although transient inhibition of P-ERK by vemurafenib was observed in colorectal cancer, rapid ERK reactivation occurred through epidermal growth factor receptor (EGFR)-mediated activation of RAS and CRAF. BRAF-mutant colorectal cancers expressed greater levels of phospho-EGFR than BRAF-mutant melanomas, suggesting that colorectal cancers are specifically poised for EGFR-mediated resistance. Combined RAF and EGFR inhibition blocked reactivation of mitogen-activated protein kinase (MAPK) signaling in BRAF-mutant colorectal cancer cells and markedly improved efficacy in vitro and in vivo. These findings support the evaluation of combined RAF and EGFR inhibition in patients with BRAF-mutant colorectal cancer. Significance: BRAF valine 600 (V600) mutations occur in 10% to 15% of colorectal cancers, yet these tumors show a surprisingly low clinical response rate (∼5%) to selective RAF inhibitors such as vemurafenib, which have produced dramatic response rates (60%–80%) in melanomas harboring the identical BRAF V600 mutation. We found that EGFR-mediated MAPK pathway reactivation leads to resistance to vemurafenib in BRAF-mutant colorectal cancers and that combined RAF and EGFR inhibition can lead to sustained MAPK pathway suppression and improved efficacy in vitro and in tumor xenografts. Cancer Discovery; 2(3); 227–35. ©2012 AACR. This article is highlighted in the In This Issue feature, p. 193
- Published
- 2012
21. The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
- Author
-
Lydia Lee, Jatin Roper, Wei-Wei Chen, Larissa Georgeon Richard, Peng Chieh Chen, Roderick T. Bronson, Kenneth E. Hung, Wei Vivian Wang, Eric S. Martin, Erin M. Coffee, Mark J. Sinnamon, and Michael P. Richardson
- Subjects
Angiogenesis ,Colorectal cancer ,Cancer Treatment ,lcsh:Medicine ,Apoptosis ,mTORC2 ,Mice ,Phosphatidylinositol 3-Kinases ,0302 clinical medicine ,Molecular Cell Biology ,Gastrointestinal Cancers ,Basic Cancer Research ,Signaling in Cellular Processes ,lcsh:Science ,Phosphoinositide-3 Kinase Inhibitors ,Mice, Knockout ,0303 health sciences ,Multidisciplinary ,Cell Death ,Colon Adenocarcinoma ,Imidazoles ,Immunohistochemistry ,3. Good health ,Oncology ,030220 oncology & carcinogenesis ,Quinolines ,Medicine ,Colorectal Neoplasms ,Research Article ,Signal Transduction ,Class I Phosphatidylinositol 3-Kinases ,Blotting, Western ,Gastroenterology and Hepatology ,Biology ,Rectal Cancer ,03 medical and health sciences ,In vivo ,Cell Line, Tumor ,Gastrointestinal Tumors ,medicine ,Animals ,Humans ,neoplasms ,Protein Kinase Inhibitors ,PI3K/AKT/mTOR pathway ,030304 developmental biology ,Cell Proliferation ,Cell growth ,lcsh:R ,Cancers and Neoplasms ,medicine.disease ,HCT116 Cells ,Molecular biology ,Cancer research ,lcsh:Q ,Tor Signaling ,Ex vivo - Abstract
Purpose To examine the in vitro and in vivo efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA wild-type colorectal cancer (CRC). Experimental Design PIK3CA mutant and wild-type human CRC cell lines were treated in vitro with NVP-BEZ235, and the resulting effects on proliferation, apoptosis, and signaling were assessed. Colonic tumors from a genetically engineered mouse (GEM) model for sporadic wild-type PIK3CA CRC were treated in vivo with NVP-BEZ235. The resulting effects on macroscopic tumor growth/regression, proliferation, apoptosis, angiogenesis, and signaling were examined. Results In vitro treatment of CRC cell lines with NVP-BEZ235 resulted in transient PI3K blockade, sustained decreases in mTORC1/mTORC2 signaling, and a corresponding decrease in cell viability (median IC50 = 9.0–14.3 nM). Similar effects were seen in paired isogenic CRC cell lines that differed only in the presence or absence of an activating PIK3CA mutant allele. In vivo treatment of colonic tumor-bearing mice with NVP-BEZ235 resulted in transient PI3K inhibition and sustained blockade of mTORC1/mTORC2 signaling. Longitudinal tumor surveillance by optical colonoscopy demonstrated a 97% increase in tumor size in control mice (p = 0.01) vs. a 43% decrease (p = 0.008) in treated mice. Ex vivo analysis of the NVP-BEZ235-treated tumors demonstrated a 56% decrease in proliferation (p = 0.003), no effects on apoptosis, and a 75% reduction in angiogenesis (p = 0.013). Conclusions These studies provide the preclinical rationale for studies examining the efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA wild-type CRC.
- Published
- 2011
22. Increased prevalence of mutant null alleles that cause hereditary fructose intolerance in the American population
- Author
-
Laura Yerkes, Elizabeth P. Ewen, Tiffany Zee, Erin M. Coffee, and Dean R. Tolan
- Subjects
Genotype ,Hereditary fructose intolerance ,Biopsy ,Nonsense mutation ,Population ,Mutation, Missense ,Oligonucleotides ,Compound heterozygosity ,Article ,Fructose-Bisphosphate Aldolase ,Genetics ,medicine ,Prevalence ,Humans ,Allele ,education ,Genetics (clinical) ,Alleles ,DNA Primers ,education.field_of_study ,biology ,Aldolase B ,Nucleic Acid Hybridization ,DNA ,medicine.disease ,Null allele ,Fructose Intolerance ,United States ,Liver ,Mutation ,biology.protein - Abstract
Mutations in the aldolase B gene (ALDOB) impairing enzyme activity toward fructose-1-phosphate cleavage cause hereditary fructose intolerance (HFI). Diagnosis of the disease is possible by identifying known mutant ALDOB alleles in suspected patients; however, the frequencies of mutant alleles can differ by population. Here, 153 American HFI patients with 268 independent alleles were analyzed to identify the prevalence of seven known HFI-causing alleles (A149P, A174D, N334K, Delta4E4, R59Op, A337V, and L256P) in this population. Allele-specific oligonucleotide hybridization analysis was performed on polymerase chain reaction (PCR)-amplified genomic DNA from these patients. In the American population, the missense mutations A149P and A174D are the two most common alleles, with frequencies of 44% and 9%, respectively. In addition, the nonsense mutations Delta4E4 and R59Op are the next most common alleles, with each having a frequency of 4%. Together, the frequencies of all seven alleles make up 65% of HFI-causing alleles in this population. Worldwide, these same alleles make up 82% of HFI-causing mutations. This difference indicates that screening for common HFI alleles is more difficult in the American population. Nevertheless, a genetic screen for diagnosing HFI in America can be improved by including all seven alleles studied here. Lastly, identification of HFI patients presenting with classic symptoms and who have homozygous null genotypes indicates that aldolase B is not required for proper development or metabolic maintenance.
- Published
- 2009
23. Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations
- Author
-
Erin M. Coffee, Leanne G. Ahronian, Levi A. Garraway, Eliezer M. Van Allen, Jason E. Faris, Ryan B. Corcoran, Eunice L. Kwak, A. John Iafrate, Nikhil Wagle, and Jeffrey A. Engelman
- Subjects
MAPK/ERK pathway ,Cancer Research ,Oncogene ,Kinase ,MEK inhibitor ,Melanoma ,Biology ,Bioinformatics ,medicine.disease_cause ,medicine.disease ,digestive system diseases ,Oncology ,Cancer research ,medicine ,KRAS ,ARAF ,neoplasms ,EGFR inhibitors - Abstract
BRAFmutations occur in ∼10% of colorectal cancers (CRCs) and confer poor prognosis. While RAF inhibitor monotherapy leads to response rates of ∼60% in BRAF mutant melanoma, response rates in BRAF mutant CRC are disappointingly low (∼5%), suggesting a fundamental difference between these tumor types, despite the mutual presence of a BRAF V600 mutation. Previously, our group and others found that while RAF inhibitors lead to profound and sustained suppression of MAPK signaling in BRAF mutant melanoma cells, suppression of MAPK signaling by RAF inhibitors in BRAF mutant CRC cells is transient, and the MAPK pathway is rapidly reactivated despite the continued presence of drug. These data suggest that MAPK pathway suppression by RAF inhibitors alone may be inadequate in BRAF mutant CRC and that combinations of RAF inhibitors with other targeted agents might be required to achieve robust MAPK suppression and clinical responses. More recently, our group and others found that in many BRAF mutant CRCs, MAPK pathway reactivation is driven by feedback signaling through EGFR via RAS and CRAF. Importantly, we found that the combination of a RAF inhibitor and an EGFR inhibitor can lead to sustained MAPK suppression and improved efficacy, leading to marked tumor regressions in preclinical BRAF mutant CRC xenograft models. These data have led to clinical trials in BRAF mutant CRC patients evaluating RAF inhibitor combinations, including combinations of RAF+EGFR, RAF+MEK, and RAF+MEK+EGFR inhibitors. Initial data from these trials, reported at ASCO 2014, have shown encouraging efficacy, with some trials showing initial response rates of as much as 40%. However, as with all targeted therapies, clinical benefit is invariably limited by the emergence of acquired resistance to these therapies. In this study, we sought to identify clinically relevant mechanisms of acquired resistance to RAF inhibitor combinations in BRAF mutant CRC, in order to understand the signaling changes leading to resistance and to devise therapeutic strategies to overcome or prevent resistance. To do so, we obtained tumor biopsies from BRAF mutant CRC patients upon disease progression, after initial response or prolonged stable disease on RAF+EGFR, RAF+MEK, or RAF+MEK+EGFR inhibitor combinations. Matched pre-treatment, post-progression, and normal DNA were analyzed by whole exome sequencing (WES) and RNA sequencing. To supplement this approach, in vitro modeling of acquired resistance was performed in BRAF mutant CRC cell lines. In one BRAF mutant CRC patient with prolonged stable disease on a RAF+EGFR inhibitor combination, WES identified KRAS amplification in a progressing lesion. RNA sequencing confirmed KRAS transcript overexpression, and KRAS amplification (∼25-fold) was confirmed by FISH in the post-progression biopsy, but was absent in a pre-treatment biopsy. Interestingly, in resistant clones generated from BRAF mutant CRC cell lines selected with either RAF+EGFR or RAF+MEK inhibitor combinations, KRAS exon 2 mutations were identified. Either KRAS amplification or KRAS mutation led to sustained MAPK pathway activity and cross-resistance to either RAF+EGFR or RAF+MEK inhibitor combinations. However, an ERK inhibitor, either alone or in combination with a RAF inhibitor retained the ability to suppress the MAPK pathway and could overcome resistance. In a second patient with a minor response to a RAF+EGFR inhibitor combination, BRAF amplification was identified in a progressing lesion, which was confirmed by FISH and was not present in a pre-treatment biopsy of the same lesion. Previously, our laboratory found that amplification of mutant BRAF could cause resistance to RAF or MEK inhibitors in BRAF mutant CRC cells by abrogating the ability of these inhibitors to suppress MAPK signaling. Importantly, an ERK inhibitor, either alone or in combination with a RAF inhibitor could suppress MAPK signaling and overcome resistance in this setting. In one patient with a minor response to a RAF+MEK inhibitor combination, WES identified the presence of an ARAF Q489L mutation and a MEK1 F53L mutation in a single progressing lesion, suggesting possible intra-lesional heterogeneity of acquired resistance mechanisms. However, utilizing a cell line derived from the patient's post-progression biopsy, we found that 30 out of 30 single cell clones harbored both the ARAF and MEK1 mutations, and that the MEK1 F53L seemed to function as the primary driver of acquired resistance in these resistant tumor cells. MEK1 F53L expression markedly abrogated the ability of RAF+MEK and RAF+EGFR inhibitor combinations to suppress MAPK signaling. Interestingly, an ERK inhibitor was able to effectively suppress MAPK signaling and overcome resistance. In a second patient with a minor response to RAF+MEK, WES identified a focal amplicon on chromosome 2 in a progressing lesion, encompassing the c-mer oncogene (MERTK) receptor tyrosine kinase and the MAPK-regulated checkpoint kinase BUB1. Post-progression biopsies from two patients who progressed after prolonged stable disease to the triple combination of a RAF+MEK+EGFR inhibitor combination are currently being analyzed by WES, and updated results will be presented. In summary, RAF inhibitor combinations are leading to promising initial response rates in recent clinical trials in BRAF mutant CRC patients. The frequent identification of alterations leading to reactivation of MAPK pathway signaling upon clinical acquired resistance to RAF+EGFR or RAF+MEK combinations underscores the MAPK pathway as a valid and critical target in BRAF mutant CRC. Importantly, we found that many of these resistance mechanisms could be overcome by an ERK inhibitor or ERK inhibitor-based combinations, suggesting that ERK inhibitors may be key components of therapeutic combinations to be explored in future clinical trials for BRAF mutant CRC. Further efforts to understand acquired resistance mechanisms will be vital to developing novel therapeutic strategies to overcome resistance and extend clinical benefit in this lethal CRC subtype. Citation Format: Ryan B. Corcoran, Leanne G. Ahronian, Eliezer Van Allen, Erin M. Coffee, Nikhil Wagle, Eunice L. Kwak, Jason E. Faris, A. John Iafrate, Levi A. Garraway, Jeffrey A. Engelman. Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr NG04. doi:10.1158/1538-7445.AM2015-NG04
- Published
- 2015
24. 428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations
- Author
-
Leanne G. Ahronian, Erin M. Coffee, Eunice L. Kwak, E.M. Van Allen, Ryan B. Corcoran, Jeffrey A. Engelman, Jason E. Faris, N Wagle, A.J. Iafrate, and L. A. Garraway
- Subjects
MAPK/ERK pathway ,Cancer Research ,Colorectal cancer ,business.industry ,Melanoma ,MEK inhibitor ,medicine.disease ,medicine.disease_cause ,Oncology ,medicine ,Cancer research ,KRAS ,ARAF ,business ,Exome sequencing ,EGFR inhibitors - Abstract
Background: BRAF mutations occur in ~10% of CRC and confer poor prognosis. While RAF inhibitor monotherapy leads to response rates of 60−80% in BRAF mutant (BRAFm) melanoma, response rates in BRAFm CRC are poor (~5%). Promising recent studies with RAF inhibitor-based combinations, including combined RAF/EGFR or RAF/MEK inhibition, have produced higher response rates in BRAFm CRC, but a better understanding of acquired resistance mechanisms will be critical to improving therapy. Methods: Mechanisms of acquired resistance to RAF/EGFR or RAF/MEK inhibition were evaluated in BRAFm CRC cell lines and in clinical biopsies obtained from BRAFm CRC patients following disease progression after initial response or prolonged stable disease to either therapeutic combination. BRAFm CRC cell lines were cultured in the presence of combined RAF/EGFR or RAF/MEK inhibitors until resistant clones emerged. Candidate resistance mutations were identified through exome sequencing. Matched pre-treament, post-progression, and normal DNA from BRAFm CRC patients treated with either RAF/EGFR or RAF/MEK combinations were analyzed by whole exome sequencing to identify clinical acquired resistance mechanisms. Results: In resistant clones generated from BRAFm CRC cell lines selected with either RAF/EGFR or RAF/MEK inhibitor combinations, KRAS exon 2 mutations were identified. KRAS mutation led to sustained MAPK pathway activity and cross-resistance to either RAF/EGFR or RAF/MEK inhibitor combinations. Interestingly, the triple combination of RAF/EGFR/MEK inhibition was able to suppress MAPK activity and overcome resistance. In a BRAFm CRC patient with prolonged stable disease on a RAF/EGFR inhibitor combination, whole exome sequencing identified the presence of KRAS amplification in a progressing lesion. RNA sequencing of the same lesion confirmed KRAS transcript overexpression, and ~25-fold amplification of KRAS in the progressing lesion and absence of amplification in the pre-treatment biopsy was confirmed by FISH. In one patient with a minor response to a RAF/MEK inhibitor combination, whole exome sequencing identified amplification of the c-mer oncogene (MERTK) receptor tyrosine kinase as the likely acquired resistance mechanism. In another patient with a minor response to a RAF/MEK inhibitor combination, whole exome sequencing identified subclonal ARAF and MEK1 mutations in the post-progression biopsy, suggesting the presence of heterogeneous acquired resistance mechanisms in this progressing lesion. Conclusions: The identification of alterations affecting the MAPK pathway in BRAFm CRC patients who have developed clinical acquired resistance to RAF/EGFR or RAF/MEK inhibitor regimens underscores the importance of the MAPK pathway in this cancer. Understanding the mechanisms of acquired resistance can lead to novel combination strategies to overcome or delay resistance. Friday 21 November 2014
- Published
- 2014
25. Abstract 3135: Pre-treatment p-EGFR levels in tumors from a genetically engineered mouse model of BRAFV600E colorectal cancer predict response to combined BRAF/EGFR inhibition
- Author
-
Jeffrey A. Engelman, Ryan B. Corcoran, and Erin M. Coffee
- Subjects
Trametinib ,Cancer Research ,Combination therapy ,business.industry ,Colorectal cancer ,MEK inhibitor ,Cancer ,Dabrafenib ,medicine.disease ,digestive system diseases ,Oncology ,Immunology ,Cancer research ,Medicine ,Erlotinib ,business ,neoplasms ,medicine.drug ,EGFR inhibitors - Abstract
BRAFV600E colorectal cancer (CRC) patients do not exhibit responses to single-agent BRAF inhibition due to activation of EGFR. While combined BRAF and EGFR inhibition has shown some success in early clinical trials, there are still a subset of patients who do not respond to this combination. The purpose of this study is to identify which BRAFV600E tumors would be expected to respond to combined BRAF/EGFR inhibition based on the pre-treatment levels of pEGFR. A genetically engineered mouse model (GEMM) for Apc-/- BrafV600E/+ p53-/- CRC was used for the study. Tumors were induced in the colons using adenovirus expressing Cre recombinase. Tumors were visualized by optical colonoscopy and pre-treatment tissue biopsy samples were obtained. BRAF mutant mice were randomized to a combination treatment with a BRAF inhibitor (Dabrafenib), combined with either an EGFR inhibitor (Erlotinib) or a MEK inhibitor (Trametinib). Tumor growth or regression was followed for 21 days by colonoscopy. A retrospective analysis indicated that those tumors with high pre-treatment phosphorylated EGFR (p-EGFR) levels had significant responses to combined BRAF/EGFR therapy, while those tumors with little to no response to combined BRAF/EGFR therapy had low levels of p-EGFR prior to treatment. Furthermore, the majority of tumors that had a significant response to the combined BRAF/MEK therapy had the lowest levels of pre-treatment p-EGFR. These pre-clinical data suggest that BRAFV600E CRC patients could benefit from being stratified by p-EGFR levels prior to treatment. Those patients with high p-EGFR levels would be expected to respond best to combined BRAF/EGFR treatment, while those patients with low p-EGFR levels might benefit from a different combination therapy, such as combined BRAF/MEK inhibition. Citation Format: Erin M. Coffee, Ryan B. Corcoran, Jeffrey A. Engelman. Pre-treatment p-EGFR levels in tumors from a genetically engineered mouse model of BRAFV600E colorectal cancer predict response to combined BRAF/EGFR inhibition. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3135. doi:10.1158/1538-7445.AM2014-3135
- Published
- 2014
26. Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
- Author
-
Miguel Rivera, Aaron N. Hata, Alan T. Yeo, David P. Kodack, Ah Ting Tam, Jeffrey A. Engelman, Kenneth E. Hung, Carlotta Costa, Sridhar Ramaswamy, Jessica L. Boisvert, Erin M. Coffee, Youngchul Song, Jatin Roper, Cyril H. Benes, Rakesh K. Jain, Randy J. Milano, Anahita Dastur, Anthony C. Faber, Ryan B. Corcoran, Elena J, and Hiromichi Ebi
- Subjects
Cancer Research ,Navitoclax ,business.industry ,Colorectal cancer ,medicine.medical_treatment ,Mutant ,Cancer ,medicine.disease ,medicine.disease_cause ,digestive system diseases ,Targeted therapy ,chemistry.chemical_compound ,Oncology ,chemistry ,Apoptosis ,Immunology ,Cancer research ,Medicine ,KRAS ,business ,neoplasms ,PI3K/AKT/mTOR pathway - Abstract
Colorectal cancers (CRCs) harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug screen, we have developed a novel therapeutic strategy that combines targeting of the apoptotic machinery using the BCL-2 family inhibitor ABT-263 (navitoclax) in combination with a TORC1/2 inhibitor, AZD8055. This combination leads to efficient apoptosis specifically in KRAS mutant (MT) and BRAF MT but not wild-type (WT) CRC cells. This specific susceptibility results from TORC1/2 inhibition leading to suppression of MCL-1 expression in mutant, but not wild-type CRCs, leading to abrogation of BIM/MCL-1 complexes. This combination strategy leads to tumor regressions in both KRAS MT colorectal cancer xenograft and genetically-engineered mouse models of CRC, but not in the corresponding KRAS WT CRC models. These data suggest that the combination of BCL-2/XL inhibitors with TORC1/2 inhibitors constitutes a promising targeted therapy strategy to treat these recalcitrant cancers. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C263. Citation Format: Erin M. Coffee, Anthony C. Faber, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy J. Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C263.
- Published
- 2013
27. Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models
- Author
-
Erin M. Coffee, Katherine A. Cheng, Jeffrey A. Engelman, Dora Dias-Santagata, Mari Mino-Kenudson, Jeffrey Settleman, Youngchul Song, Patricia Greninger, Jason T. Godfrey, Cyril H. Benes, Toshi Shioda, Ronald D. Brown, Anurag K. Singh, Kwok-Kin Wong, Eugene Lifshits, Hiromichi Ebi, Travis J. Cohoon, Anthony C. Faber, Ryan B. Corcoran, and Aaron N. Hata
- Subjects
Cancer Research ,Navitoclax ,Oncogene ,biology ,MEK inhibitor ,medicine.medical_treatment ,Cancer ,Bcl-xL ,medicine.disease_cause ,medicine.disease ,Targeted therapy ,chemistry.chemical_compound ,Oncology ,chemistry ,Immunology ,Cancer cell ,Cancer research ,medicine ,biology.protein ,KRAS - Abstract
Although KRAS is the most commonly mutated oncogene in human cancer, KRAS has proven difficult to target pharmacologically, and no effective therapies exist for KRAS-mutant cancers. Recently, there has been evidence that targeted therapy combinations inhibiting multiple downstream effectors of KRAS may be a promising approach for KRAS-mutant cancers. We developed a pooled shRNA-drug screen strategy to identify genes that, when inhibited, cooperate with MEK inhibitors to kill KRAS-mutant cancer cells. The anti-apoptotic BH3 family gene BCL-XL emerged as a top hit through this approach. ABT-263 (navitoclax), a chemical inhibitor that blocks the ability of BCL-XL to bind and inhibit pro-apoptotic proteins, in combination with a MEK inhibitor led to dramatic apoptosis in the vast majority of KRAS-mutant cell lines tested from different tissue types. Mechanistic studies revealed that MEK inhibition led to marked induction of the pro-apoptotic protein BIM in KRAS-mutant cancer cells, but that BIM remained bound and inhibited by BCL-XL. Pharmacologic inhibition of BCL-XL with ABT-263 disrupted this inhibitory complex, allowing BIM to trigger apoptosis. Epithelial differentiation and E-cadherin expression correlated with increased sensitivity to this inhibitor combination across a panel of 30 KRAS-mutant cell lines, while epithelial-to-mesenchymal transition (EMT) correlated with resistance. This combination also caused marked in vivo tumor regressions in three independent KRAS-mutant xenografts and in established lung tumors in two genetically-engineered KRAS-driven lung cancer mouse models. These data support combined BCL-XL/MEK inhibition as a promising therapeutic approach for evaluation in future clinical trials for patients with KRAS-mutant cancers. This abstract is also presented as Poster B19. Citation Format: Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason T. Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Toshi Shioda, Dora Dias-Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino-Kenudson, Kwok-Kin Wong, Jeffrey A. Engelman. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities; May 17-20, 2013; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(5 Suppl):Abstract nr PR09.
- Published
- 2013
28. Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling
- Author
-
Jennifer A. Wargo, Kenneth E. Hung, Adriano Piris, Jeffrey Settleman, Jeffrey A. Engelman, Dora Dias-Santagata, Hiromichi Ebi, Ronald D. Brown, Mari Mino-Kenudson, Michiya Nishino, Erin M. Coffee, Keith T. Flaherty, Ryan B. Corcoran, Patricia Della Pelle, Alexa B. Turke, and Alexandria P. Cogdill
- Subjects
MAPK/ERK pathway ,Cancer Research ,endocrine system diseases ,Colorectal cancer ,business.industry ,Melanoma ,Mutant ,medicine.disease ,Primary tumor ,digestive system diseases ,Oncology ,In vivo ,Cell culture ,Immunology ,medicine ,Cancer research ,business ,Vemurafenib ,neoplasms ,medicine.drug - Abstract
BRAF mutations occur in 10–15% of colorectal cancers (CRCs) and confer adverse outcome in the metastatic setting. While RAF inhibitors such as vemurafenib (PLX4032) have proven effective in BRAF mutant melanoma (∼60–80% response rates), they are surprisingly ineffective in BRAF mutant CRCs (∼5% response rate), and the reason for this disparity remains unclear. Compared to BRAF mutant melanoma cells, BRAF mutant CRC cells were less sensitive to vemurafenib, and P-ERK suppression was not sustained in response to treatment. Although transient inhibition of phospho-ERK by vemurafenib was observed in CRC, rapid ERK re-activation occurred through EGFR-mediated activation of RAS and CRAF. BRAF mutant CRC cell lines and patient tumor specimens expressed significantly higher levels of phospho-EGFR than BRAF mutant melanoma cell lines and primary tumor specimens, suggesting that CRCs are specifically poised for EGFR-mediated resistance. Combined RAF and EGFR inhibition blocked reactivation of MAPK signaling in BRAF mutant CRC cells and markedly improved efficacy in vitro. In vivo, combined RAF and EGFR inhibition led to sustained suppression of MAPK signaling and to robust tumor regressions in BRAF mutant colorectal xenografts. These findings support evaluation of combined RAF and EGFR inhibition in clinical trials in patients with BRAF mutant CRC. This proffered talk is also presented as Poster B11.
- Published
- 2012
29. 647 Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAFV600E Colon Cancer
- Author
-
Jatin Roper, Kenneth E. Hung, Peter J. Belmont, RamnikJ. Xavier, Erin M. Coffee, Larissa Georgeon Richard, Lily Keung, Eric S. Martin, Gautam Goel, Roderick T. Bronson, Mark J. Sinnamon, Wei Vivian Wang, and Barbara Weinstein
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,business.industry ,Colorectal cancer ,Gastroenterology ,medicine.disease ,Blockade ,Internal medicine ,Concomitant ,medicine ,Effective treatment ,business ,PI3K/AKT/mTOR pathway - Published
- 2012
30. Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib
- Author
-
Erin M. Coffee, Jeffrey Settleman, Ryan B. Corcoran, Alexandra P. Cogdill, Adriano Piris, Ronald D. Brown, Dora Dias-Santagata, Hiromichi Ebi, Mari Mino-Kenudson, Jeffrey A. Engelman, Alexa B. Turke, Patricia Della Pelle, Jennifer A. Wargo, Kenneth E. Hung, Keith T. Flaherty, and Michiya Nishino
- Subjects
MAPK/ERK pathway ,Cancer Research ,business.industry ,Melanoma ,Mutant ,Cancer ,medicine.disease ,Primary tumor ,digestive system diseases ,Oncology ,In vivo ,Cell culture ,Immunology ,Cancer research ,Medicine ,business ,Vemurafenib ,neoplasms ,medicine.drug - Abstract
Oncogenic BRAF mutations occur in 10-15% of colorectal cancers (CRCs) and confer adverse outcome. While RAF inhibitors such as vemurafenib (PLX4032) have produced dramatic response rates in BRAF mutant melanoma (∼60-80%), they are surprisingly ineffective in BRAF mutant CRCs (∼5% response rate), and the reason for this disparity remains unclear. Compared to BRAF mutant melanoma cells, BRAF mutant CRC cells were less sensitive to vemurafenib, and P-ERK suppression was not sustained in response to treatment. Although transient inhibition of phospho-ERK by vemurafenib was observed in CRC, rapid ERK re-activation occurred through EGFR-mediated activation of RAS and CRAF. BRAF mutant CRC cell lines and patient tumor specimens expressed higher levels of phospho-EGFR than BRAF mutant melanoma cell lines and primary tumor specimens, suggesting that CRCs are specifically poised for EGFR-mediated resistance. Combined RAF and EGFR inhibition blocked reactivation of MAPK signaling in BRAF mutant CRC cells, markedly improved efficacy in vitro, and led to robust tumor regressions in vivo in BRAF mutant xenografts models. These findings support combined RAF and EGFR inhibition as a novel and promising therapeutic strategy for evaluation in clinical trials in patients with BRAF mutant CRC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-350. doi:1538-7445.AM2012-LB-350
- Published
- 2012
31. The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model for Sporadic Colorectal Cancer
- Author
-
Wei Y. Chen, Jatin Roper, Erin M. Coffee, Larissa Georgeon Richard, Kenneth E. Hung, Eric S. Martin, Lydia Lee, Wei Vivian Wang, Roderick T. Bronson, Peng Chieh Chen, and Michael P. Richardson
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,Mouse model of colorectal and intestinal cancer ,Discovery and development of mTOR inhibitors ,Sporadic colorectal cancer ,Internal medicine ,Genetically Engineered Mouse ,medicine ,Tumor regression ,business ,PI3K/AKT/mTOR pathway - Published
- 2011
32. Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- Author
-
Eugene Lifshits, Youngchul Song, Mari Mino-Kenudson, Anurag K. Singh, Patricia Greninger, Jeffrey Settleman, Ryan B. Corcoran, Travis J. Cohoon, Ronald D. Brown, Toshi Shioda, Erin M. Coffee, Anthony C. Faber, Katherine A. Cheng, Jeffrey A. Engelman, Kenneth E. Hung, Kwok-Kin Wong, Hiromichi Ebi, Dora Dias-Santagata, Aaron N. Hata, Cyril H. Benes, and Jason T. Godfrey
- Subjects
Cancer Research ,Mutant ,bcl-X Protein ,Antineoplastic Agents ,Bcl-xL ,Biology ,medicine.disease_cause ,Proto-Oncogene Proteins p21(ras) ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Neoplasms ,medicine ,Animals ,Humans ,neoplasms ,030304 developmental biology ,Sulfonamides ,0303 health sciences ,Aniline Compounds ,Navitoclax ,Oncogene ,MEK inhibitor ,Cancer ,Cell Biology ,MAP Kinase Kinase Kinases ,medicine.disease ,Molecular biology ,digestive system diseases ,respiratory tract diseases ,3. Good health ,chemistry ,Oncology ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,biology.protein ,Benzimidazoles ,KRAS ,Drug Screening Assays, Antitumor - Abstract
SummaryKRAS is the most commonly mutated oncogene, yet no effective targeted therapies exist for KRAS mutant cancers. We developed a pooled shRNA-drug screen strategy to identify genes that, when inhibited, cooperate with MEK inhibitors to effectively treat KRAS mutant cancer cells. The anti-apoptotic BH3 family gene BCL-XL emerged as a top hit through this approach. ABT-263 (navitoclax), a chemical inhibitor that blocks the ability of BCL-XL to bind and inhibit pro-apoptotic proteins, in combination with a MEK inhibitor led to dramatic apoptosis in many KRAS mutant cell lines from different tissue types. This combination caused marked in vivo tumor regressions in KRAS mutant xenografts and in a genetically engineered KRAS-driven lung cancer mouse model, supporting combined BCL-XL/MEK inhibition as a potential therapeutic approach for KRAS mutant cancers.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.